Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program
Collaboration brings together Schrödinger’s in silico discovery capabilities with SPARC’s novel insights into CNS pathways to speed drug development
MUMBAI & NEW YORK--(BUSINESS WIRE)-- Schrödinger and Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced a research collaboration to accelerate the discovery of novel CNS therapeutics by leveraging Schrödinger’s advanced computational platform and SPARC’s extensive drug development expertise and insights in neurodegeneration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181203005212/en/
Schrödinger, a privately held company committed to revolutionizing drug discovery through advanced molecular simulation, will focus on lead discovery and optimization. SPARC, a clinical-stage company focused on improving patient care through innovation, will be responsible for compound synthesis and assays.
“This research collaboration is particularly exciting because neurodegeneration is an area where we urgently need more options for patients through novel approaches to drug discovery and development,” said Ramy Farid, Ph.D., president and CEO of Schrödinger. “SPARC has been working with leading academic researchers to explore pathways relevant to disorders of the central nervous system, and their insights are quite compelling. Teaming up will allow us to rapidly interrogate therapeutic compounds that target these pathways.”
“We have used Schrödinger’s software for years and have experienced directly the power of their physics-based approaches to computational modeling, so we’re delighted to form a collaboration that lets us tap into the expertise of their drug discovery team as well,” said Anil Raghavan, CEO of SPARC. “At SPARC, we’re committed to fueling innovation through both internal R&D and strategic partnerships with industry leaders, and this collaboration is a strong step in that direction. By working together, we can greatly accelerate the pace of innovation.”
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions that accelerate and increase the efficiency of drug discovery and materials design. Schrödinger has a growing pipeline of early stage assets and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic. In addition, the company has deep partnerships and collaborations in such fields as biotechnology, pharmaceuticals, chemicals, and electronics. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. Founded in 1990, Schrödinger has nearly 400 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit www.schrödinger.com.
About SPARC (CIN: L73100GJ2006PLC047837):
Sun Pharma Advanced Research Company Ltd. (SPARC) is a global pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC aims to consistently lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the company can be found at www.sparc.life.
Statements in this document describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.